Current Clinical Trials

Multicenter Phase II Trial of Intratumoral pIL-12 plus Electroporation in Advanced Stage Cutaneous and in Transit Malignant Melanoma

OBJECTIVES: Assess the safety and overall objective response rate by modified “skin” RECIST criteria of intratumoral injection of pIL-12 electroporation in patients with in-transit cutaneous and subcutaneous metastatic melanoma


STATUS: Recruiting Learn More

Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients with Triple Negative Breast Cancer

OBJECTIVES: Evaluate the potential of intratumoral treatment with pIL-12 delivered via electroporation to promote a pro-inflammatory molecular and histological signature in patients with triple negative breast cancer


STATUS: Recruiting Learn More

Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma through Intratumoral pIL-12 Electroporation

OBJECTIVES: Assess the anti-tumor efficacy (defined as the best overall response rate using RECIST v1.1) and safety of the combination of plasmid interleukin-12 electroporation and pembrolizumab in patients with low tumor-infiltrating lymphocyte (TIL) melanoma †

†This is a collaboration with University of California, San Francisco


STATUS: Recruiting Learn More
Real Time Web Analytics